JIP
GNOM icon

Jaffetilchin Investment Partners’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Jaffetilchin Investment Partners’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10
Closed -$461 – 737
2024
Q3 		$461 Buy
+10
New +$447 ﹤0.01% 1296
2022
Q1 		– Sell
-16,875
Closed -$1.34M – 347
2021
Q4 		$1.34M Buy
+16,875
New +$1.42M 0.13% 109

Other funds holding GNOM

OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Mirae Asset Global ETFs Holdings
Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jaffetilchin Investment Partners's GNOM Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2024, closing a stake of 10 shares — an estimated $461 sold.

Jaffetilchin Investment Partners first reported a position in GNOM in Q4 2021 and held it in 2 quarters. The position peaked at $1.34M in Q4 2021. 69 funds tracked by Wall St. Rank hold GNOM as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 10 Global X Genomics & Biotechnology ETF shares in Q4 2024, an estimated $461.
  • Jaffetilchin Investment Partners first reported a position in Global X Genomics & Biotechnology ETF in Q4 2021 and held it in 2 quarters.
  • Jaffetilchin Investment Partners's Global X Genomics & Biotechnology ETF position peaked at $1.34M in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.